239 related articles for article (PubMed ID: 2533159)
1. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Furr BJ
Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
[TBL] [Abstract][Full Text] [Related]
2. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
3. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
Kennealey GT; Furr BJ
Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
[TBL] [Abstract][Full Text] [Related]
4. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Furr BJ
Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
[No Abstract] [Full Text] [Related]
5. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Mahler C; Verhelst J; Denis L
Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
7. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
8. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Schröder FH
Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic drugs.
McLeod DG
Cancer; 1993 Feb; 71(3 Suppl):1046-9. PubMed ID: 8428326
[TBL] [Abstract][Full Text] [Related]
10. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Sarosdy MF
Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
[TBL] [Abstract][Full Text] [Related]
11. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
12. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
[TBL] [Abstract][Full Text] [Related]
13. Casodex: preclinical studies.
Furr BJ
Eur Urol; 1990; 18 Suppl 3():2-9. PubMed ID: 2094608
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Maucher A; von Angerer E
J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogens as monotherapy for prostate cancer.
Schröder FH
Eur Urol; 1998; 34 Suppl 3():12-7. PubMed ID: 9854190
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Soloway MS; Matzkin H
Cancer; 1993 Feb; 71(3 Suppl):1083-8. PubMed ID: 8428332
[TBL] [Abstract][Full Text] [Related]
18. The place and the results of monotherapy.
Bonnet P
Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
[No Abstract] [Full Text] [Related]
19. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Sciarra A; Cardi A; Di Silverio F
Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
[TBL] [Abstract][Full Text] [Related]
20. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
Freeman SN; Mainwaring WI; Furr BJ
Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
